131 related articles for article (PubMed ID: 28365185)
1. Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells.
Revalde JL; Li Y; Wijeratne TS; Bugde P; Hawkins BC; Rosengren RJ; Paxton JW
Eur J Pharmacol; 2017 May; 803():167-173. PubMed ID: 28365185
[TBL] [Abstract][Full Text] [Related]
2. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
3. Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance.
Revalde JL; Li Y; Hawkins BC; Rosengren RJ; Paxton JW
Biochem Pharmacol; 2015 Feb; 93(3):305-17. PubMed ID: 25543853
[TBL] [Abstract][Full Text] [Related]
4. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Nishio R; Tsuchiya H; Yasui T; Matsuura S; Kanki K; Kurimasa A; Hisatome I; Shiota G
Cancer Sci; 2011 Mar; 102(3):622-9. PubMed ID: 21205085
[TBL] [Abstract][Full Text] [Related]
5. EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1.
Weadick B; Nayak D; Persaud AK; Hung SW; Raj R; Campbell MJ; Chen W; Li J; Williams TM; Govindarajan R
Mol Cancer Ther; 2021 Feb; 20(2):410-422. PubMed ID: 33298588
[TBL] [Abstract][Full Text] [Related]
6. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1.
Hu Q; Qin Y; Zhang B; Liang C; Ji S; Shi S; Xu W; Xiang J; Liang D; Ni Q; Yu X; Xu J
Oncol Rep; 2017 Oct; 38(4):2069-2077. PubMed ID: 28765935
[TBL] [Abstract][Full Text] [Related]
7. Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling.
Miller SR; Zhang X; Hau RK; Jilek JL; Jennings EQ; Galligan JJ; Foil DH; Zorn KM; Ekins S; Wright SH; Cherrington NJ
Mol Pharmacol; 2021 Feb; 99(2):147-162. PubMed ID: 33262250
[TBL] [Abstract][Full Text] [Related]
8. Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.
Xu H; Li Y; Paxton JW; Wu Z
Pharm Res; 2021 Jul; 38(7):1209-1219. PubMed ID: 34189639
[TBL] [Abstract][Full Text] [Related]
9. Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells.
Hioki M; Shimada T; Yuan T; Nakanishi T; Tajima H; Yamazaki M; Yokono R; Takabayashi M; Sawamoto K; Akashita G; Miyamoto KI; Ohta T; Tamai I; Shimada T; Sai Y
Biopharm Drug Dispos; 2018 May; 39(5):256-264. PubMed ID: 29682747
[TBL] [Abstract][Full Text] [Related]
10. Visualization research on ENT1/NIS dual-function gene therapy to reverse drug resistance mediated by MUC1 in GEM-resistant pancreatic cancer.
Xi Y; Chen H; Xi Y; Hai W; Qu Q; Zhang M; Li B
Nucl Med Biol; 2023; 120-121():108350. PubMed ID: 37229950
[TBL] [Abstract][Full Text] [Related]
11. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1.
Wang H; Word BR; Lyn-Cook BD
Anticancer Res; 2011 Oct; 31(10):3171-80. PubMed ID: 21965724
[TBL] [Abstract][Full Text] [Related]
12. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
13. Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.
Espinoza JA; García P; Bizama C; Leal JL; Riquelme I; Weber H; Macanas P; Aguayo G; Viñuela E; Roa JC; Nervi B
Histopathology; 2016 Apr; 68(5):722-8. PubMed ID: 26266900
[TBL] [Abstract][Full Text] [Related]
14. Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors.
Jouan E; Moreau A; Bruyere A; Alim K; Denizot C; Parmentier Y; Fardel O
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):625-635. PubMed ID: 34275128
[TBL] [Abstract][Full Text] [Related]
15. Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells.
Choi MK
Arch Pharm Res; 2012 May; 35(5):921-7. PubMed ID: 22644860
[TBL] [Abstract][Full Text] [Related]
16. Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity.
Hammond JR
Naunyn Schmiedebergs Arch Pharmacol; 2000 Apr; 361(4):373-82. PubMed ID: 10763851
[TBL] [Abstract][Full Text] [Related]
17. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells.
Wu P; Wang X; Ma Y; Xu X; Liu W; Sheng Z; Chen M; Zhou R; Zhang K; Goodin S; Zheng X; Li D
Bioorg Chem; 2020 Aug; 101():104022. PubMed ID: 32599367
[TBL] [Abstract][Full Text] [Related]
18. Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Ueda K; Masuda A; Fukuda M; Tanaka S; Hosokawa M; Iwakawa S
Drug Metab Pharmacokinet; 2017 Dec; 32(6):301-310. PubMed ID: 29174536
[TBL] [Abstract][Full Text] [Related]
19. Fluorouracil uptake in triple-negative breast cancer cells: Negligible contribution of equilibrative nucleoside transporters 1 and 2.
Noguchi S; Takagi A; Tanaka T; Takahashi Y; Pan X; Kibayashi Y; Mizokami R; Nishimura T; Tomi M
Biopharm Drug Dispos; 2021 Mar; 42(2-3):85-93. PubMed ID: 33426680
[TBL] [Abstract][Full Text] [Related]
20. Affinity, binding kinetics and functional characterization of draflazine analogues for human equilibrative nucleoside transporter 1 (SLC29A1).
Vlachodimou A; Konstantinopoulou K; IJzerman AP; Heitman LH
Biochem Pharmacol; 2020 Feb; 172():113747. PubMed ID: 31830468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
